TOKYO, April 26, 2025 /PRNewswire/ -- Petal Ads, Huawei's leading global mobile advertising platform, today successfully hosted the "Think Tank 2025" seminar in Japan. The event convened prominent brands and domestic agencies from the travel, beauty, luxury goods and lifestyle services sectors to showcase Huawei's all-scenario intelligent advertising solutions built on the HarmonyOS ecosystem, offering Japanese enterprises fresh digital-marketing strategies for entering the Chinese and wider global markets.
As a technology company deeply rooted in Japan for nearly two decades, Huawei leverages its global ecosystem and the innovation of HarmonyOS to continuously empower partners' digital transformation. "Through in-depth local insights, we have built an intelligent advertising platform that connects global users," said Zhou Rong, Director of Asia-Pacific Ecosystem Development and Operations at Huawei Consumer Business Group. "Petal Ads' unique all-scenario solutions not only precisely reach segmented audiences but also help Japanese brands unlock commercial value in cross-cultural communication."
At the seminar, Yang Yang, Global Marketing Director of Huawei Ads, presented an integrated marketing strategy within the HarmonyOS ecosystem. Syaliza Abd Aziz, Japan representative of the Malaysia Tourism Promotion Board, discussed her organization's strategic partnership with Petal Ads on Visit Malaysia 2026. Colin Duan, Chief Product Officer of third-party data firm QuestMobile, used detailed analytics to decode Chinese internet users' consumption patterns in travel, beauty and other industries, providing decision-making insights for Japanese companies' local-market campaigns. Fukuzumi Ryo, co-founder of leading Japanese ad agency Unbot, shared multiple success stories on site, demonstrating Petal Ads' technical strengths in precise customer acquisition and performance conversion in Japan.
The upgraded "Think Tank 2025" marks a significant milestone in Petal Ads' globalization strategy. With three core advantages—intelligent ad technology, a premium global user base and customizable all-scenario solutions—the platform now delivers monetization services to 53,000 apps across more than 200 industries worldwide. Looking ahead, Petal Ads will deepen strategic collaborations with its Japanese partners and continue to foster more high-quality brands' international growth through an innovative digital-marketing ecosystem.
For more information, please visit: https://ads.huawei.com/
About Petal Ads
Petal Ads is Huawei Terminal Cloud Services' global commercial-service platform, dedicated to providing advertisers and developers with intelligent marketing and traffic-monetization solutions. As of March 2023, the platform spans over 200 industry verticals and operates in more than 170 countries and regions, continually empowering partners' commercial growth and brand enhancement via HarmonyOS's all-scenario intelligent distribution capabilities.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Petal Ads Hosts "Think Tank 2025" Seminar in Japan to Empower Japanese Companies' Global Expansion
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
